Oncotelic extends JH Darbie note maturity to Mar 2023; issues 33M warrants at $0.15

Oncotelic Therapeutics, Inc.

Maturity of convertible notes extended from March 31, 2022 to March 31, 2023 with all but one investor agreeing.
Company to issue 33,000,066 Oncotelic warrants at an exercise price of $0.15 per common share.
Each Unit holder receives 333,334 warrants per Unit purchased as consideration for the extension.
Notes were originally issued in July 2020 as part of JH Darbie Financing units.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.